Hussain Naseri, MD
Hematology & Oncology · Waterloo, IANPI 1154646149
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,507 of the $1,803 with a category attached, or 83.6%. It is spread thinly across 27 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,508 and has fallen 97.1% since, to $43 in 2025.
Across 77 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$314
- Amgen$256
- Genentech USA, Inc.$150
- Johnson & Johnson$147
- Eisai Inc.$129
- Pharmacyclics LLC, An Abbvie Company$127
- plus $680 from 21 others
Across 2 payments — averaging $1937.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Helsinn Healthcare SA$4K
What the payments were for
- Food & beverage$1,50784%
- Education$29616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $314 |
| Amgen | 9 | $256 |
| Genentech USA, Inc. | 5 | $150 |
| Johnson & Johnson(2 entities) | 2 | $147 |
| Eisai Inc. | 6 | $129 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $127 |
| AstraZeneca | 6 | $101 |
| Pfizer | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 1 | $70 |
| Merck | 4 | $65 |
| Bristol Myers Squibb | 3 | $60 |
| Tesaro, Inc. | 2 | $39 |
| AbbVie | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Incyte Corporation | 2 | $27 |
| Seagen Inc. | 2 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Immunogen, Inc. | 1 | $18 |
| Verastem, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,803 in reported general payments places this provider in the 70th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 49 | $832,435 |
| TagrissoOsimertinib Mesylate | 25 | $456,729 |
| KisqaliRibociclib Succinate | 31 | $434,791 |
| VenclextaVenetoclax | 26 | $420,030 |
| PyrukyndMitapivat Sulfate | 13 | $332,562 |
| Lenalidomide | 25 | $332,542 |
| ErleadaApalutamide | 15 | $218,915 |
| CalquenceAcalabrutinib Maleate | 11 | $159,244 |
| DopteletAvatrombopag Maleate | 12 | $138,533 |
| Abiraterone Acetate | 55 | $76,974 |
| EliquisApixaban | 69 | $57,352 |
| Imatinib Mesylate | 14 | $46,450 |
| XareltoRivaroxaban | 19 | $20,600 |
| Deferasirox | 12 | $6,202 |
| Anagrelide Hcl | 28 | $2,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $60 | $832,43549 claims |
| AstraZenecaTagrisso, Calquence | $101 | $615,97336 claims |
| NovartisKisqali | $314 | $434,79131 claims |
| AbbVieVenclexta | $31 | $420,03026 claims |
| Johnson & JohnsonErleada, Xarelto | $147 | $239,51434 claims |
| PfizerEliquis | $76 | $57,35269 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 75 hematology & oncology providers in Iowa.
Other hematology & oncology in Waterloo
- Mukund NadipuramWaterloo$1K
- Sakeer HussainCouncil Bluffs$74K
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Kartik AnandWest Des Moines$24K
- Donald WenderSioux City$22K
- Susannah FriemelDavenport$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.